JATT III Acquisition Corp, a Cayman Islands-incorporated special purpose acquisition company, has completed an initial public offering of 6.9 million ordinary shares at $10.00 per share, raising approximately $69 million in gross proceeds before underwriting discounts and other expenses.
The offering included an over-allotment option for 900,000 additional shares, which was fully exercised by underwriters Guggenheim Securities, LLC, the sole book-running manager. Trading on the Nasdaq Global Market under the ticker symbol JTTT began on Tuesday, following the U.S. Securities and Exchange Commission’s declaration of effectiveness for the company’s registration statement on August 25, 2026.
JATT III Acquisition, headquartered in Westfield, New Jersey, is targeting healthcare and healthcare-related businesses, with a particular focus on biotechnology and life sciences. The company’s strategy emphasizes investments in businesses leveraging data-driven approaches, including machine learning and computational biology, for drug discovery and development.
As of the IPO’s completion, JATT III has not selected a specific business combination target and has not engaged in substantive discussions regarding potential mergers, share exchanges, asset acquisitions, or similar transactions. The firm’s leadership includes Dr. Someit Sidhu as Chief Executive Officer and Chairman, and Nicholas Fernandez as Chief Financial Officer.
The IPO attracted participation from institutional investors including Adage Capital Partners, ADAR1 Capital, Affinity Asset Advisors, Columbia Threadneedle Investments, and others.
